

# Guido Rasi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3444550/publications.pdf>

Version: 2024-02-01

93  
papers

3,836  
citations

81839

39  
h-index

128225

60  
g-index

96  
all docs

96  
docs citations

96  
times ranked

4536  
citing authors

#	ARTICLE	IF	CITATIONS
1	Thymosin $\alpha$ 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling. <i>Blood</i> , 2004, 103, 4232-4239.	0.6	189
2	Nanopore Technology for Biomedical Applications. <i>Biomedical Microdevices</i> , 1999, 2, 11-40.	1.4	172
3	Thymosin $\alpha$ 1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. <i>Blood</i> , 2006, 108, 2265-2274.	0.6	172
4	From adaptive licensing to adaptive pathways: Delivering a flexible life-span approach to bring new drugs to patients. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 97, 234-246.	2.3	160
5	The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation. <i>Experimental Cell Research</i> , 2009, 315, 849-862.	1.2	125
6	Drug Policy for an Aging Population – The European Medicines Agency's Geriatric Medicines Strategy. <i>New England Journal of Medicine</i> , 2012, 367, 1972-1974.	13.9	111
7	Nerve Growth Factor: Neurotrophin or Cytokine?. <i>International Archives of Allergy and Immunology</i> , 2003, 131, 80-84.	0.9	104
8	Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. <i>Value in Health</i> , 2017, 20, 487-495.	0.1	101
9	Methodology for development of the Allergic Rhinitis and its Impact on Asthma Guideline 2008 update. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 38-46.	2.7	97
10	Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1212-1218.	2.3	97
11	Rhinitis and asthma in athletes: an ARIA document in collaboration with GA2LEN. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 681-692.	2.7	96
12	Open Clinical Trial Data for All? A View from Regulators. <i>PLoS Medicine</i> , 2012, 9, e1001202.	3.9	92
13	AQUA <sup>®</sup> : Allergy Questionnaire for Athletes. Development and Validation. <i>Medicine and Science in Sports and Exercise</i> , 2009, 41, 1034-1041.	0.2	88
14	Thymosin $\alpha$ 1: An Endogenous Regulator of Inflammation, Immunity, and Tolerance. <i>Annals of the New York Academy of Sciences</i> , 2007, 1112, 326-338.	1.8	87
15	Stimulatory effect of Eucalyptus essential oil on innate cell-mediated immune response. <i>BMC Immunology</i> , 2008, 9, 17.	0.9	87
16	The risks of risk aversion in drug regulation. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 907-916.	21.5	87
17	Microfabricated biocapsules provide short-term immunoisolation of insulinoma xenografts. <i>Biomedical Microdevices</i> , 1999, 1, 131-138.	1.4	85
18	Data Rich, Information Poor: Can We Use Electronic Health Records to Create a Learning Healthcare System for Pharmaceuticals?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 912-922.	2.3	76

#	ARTICLE	IF	CITATIONS
19	Transparency and the European Medicines Agency " Sharing of Clinical Trial Data. New England Journal of Medicine, 2014, 371, 2452-2455.	13.9	69
20	Asthma, allergy and the Olympics. Current Opinion in Allergy and Clinical Immunology, 2015, 15, 184-192.	1.1	66
21	PACAP and VIP prevent apoptosis in schwannoma cells. Brain Research, 2008, 1241, 29-35.	1.1	64
22	Access to Patient-Level Trial Data " A Boon to Drug Developers. New England Journal of Medicine, 2013, 369, 1577-1579.	13.9	62
23	Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: Evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/ $\beta$ -catenin signaling. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 1004-1018.	1.8	61
24	Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. Annals of Oncology, 2010, 21, 2081-2087.	0.6	57
25	How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice. British Journal of Clinical Pharmacology, 2016, 82, 965-973.	1.1	57
26	WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer. Oncotarget, 2014, 5, 978-992.	0.8	54
27	Thymosin $\alpha$ 1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo. International Immunology, 2007, 19, 1261-1270.	1.8	49
28	Combination therapy with thymosin $\alpha$ 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the lewis lung carcinoma in mice. International Journal of Cancer, 1992, 50, 493-499.	2.3	48
29	Combination low-dose lymphoblastoid interferon and thymosin $\alpha$ 1 therapy in the treatment of chronic hepatitis B. Journal of Viral Hepatitis, 1996, 3, 191-196.	1.0	48
30	Differentiation of human melanoma cells induced by cyanidin-3-O- $\beta$ -D-glucopyranoside. FASEB Journal, 2004, 18, 1940-1942.	0.2	48
31	Are Novel, Nonrandomized Analytic Methods Fit for Decision Making? The Need for Prospective, Controlled, and Transparent Validation. Clinical Pharmacology and Therapeutics, 2020, 107, 773-779.	2.3	48
32	TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death. Experimental Cell Research, 2011, 317, 2479-2489.	1.2	45
33	Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.. Gut, 1996, 39, 679-683.	6.1	44
34	Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. International Journal of Immunopharmacology, 2000, 22, 1067-1076.	1.1	44
35	Predictive value of allergy and pulmonary function tests for the diagnosis of asthma in elite athletes. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1166-1170.	2.7	44
36	Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee. Nature Reviews Drug Discovery, 2014, 13, 395-397.	21.5	42

#	ARTICLE	IF	CITATIONS
37	Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. <i>International Journal of Cancer</i> , 1994, 57, 701-705.	2.3	41
38	Nerve growth factor and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2002, 57, 13-15.	2.7	41
39	Thymosin Alpha 1. <i>Annals of the New York Academy of Sciences</i> , 2007, 1112, 225-234.	1.8	41
40	Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin- $\alpha$ 1 and interferon- $\gamma$ 2a. <i>European Journal of Cancer</i> , 1995, 31, 2403-2405.	1.3	40
41	Cancer Drug Development and the Evolving Regulatory Framework for Companion Diagnostics in the European Union. <i>Clinical Cancer Research</i> , 2014, 20, 1458-1468.	3.2	40
42	Drug Regulation and Pricing – Can Regulators Influence Affordability?. <i>New England Journal of Medicine</i> , 2016, 374, 1807-1809.	13.9	39
43	Nerve growth factor involvement in liver cirrhosis and hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 4986.	1.4	38
44	Thymosin $\alpha$ 1 in combination with cytokines and chemotherapy for the treatment of cancer. <i>International Immunopharmacology</i> , 2003, 3, 1145-1150.	1.7	37
45	Montelukast, a Leukotriene Receptor Antagonist, in Vernal Keratoconjunctivitis Associated With Asthma. <i>JAMA Ophthalmology</i> , 2003, 121, 615.	2.6	37
46	The impact of parallel regulatory – health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1013-1019.	1.1	34
47	Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 516-516.	21.5	32
48	Biochemotherapy with thymosin $\alpha$ 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: Clinical and immunological effects. <i>Annals of Oncology</i> , 1994, 5, 741-746.	0.6	31
49	Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2003, 3, 1169-1176.	1.7	28
50	Combined treatment with thymosin- $\alpha$ 1 and low dose interferon- $\gamma$ after dacarbazine in advanced melanoma. <i>Melanoma Research</i> , 2000, 10, 189-192.	0.6	25
51	Diagnosis of asthma and permitted use of inhaled beta2-agonists in athletes. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2004, 59, 33-36.	2.7	24
52	Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 730-733.	2.3	22
53	Feasibility of in utero DNA vaccination following naked gene transfer into pig fetal muscle: Transgene expression, immunity and safety. <i>Vaccine</i> , 2006, 24, 4586-4591.	1.7	21
54	Pharmacovigilance 2030. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 89-91.	2.3	20

#	ARTICLE	IF	CITATIONS
55	Efficacy of repeated cycles of chemo-immunotherapy with Thymosin $\hat{1}\pm 1$ and interleukin-2 after intraperitoneal 5-fluorouracil delivery. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 172-178.	2.0	19
56	Transcription profile of human lymphocytes following <i>in vitro</i> treatment with thymosin alpha $\hat{1}$ . <i>Annals of the New York Academy of Sciences</i> , 2010, 1194, 6-19.	1.8	17
57	Fifty years after thalidomide; what role for drug regulators?. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 731-733.	1.1	17
58	Immunopharmacology of Thymosin $\hat{1}\pm 1$ and Cytokine Synergy. <i>Annals of the New York Academy of Sciences</i> , 2007, 1112, 235-244.	1.8	16
59	Big Data – How to Realize the Promise. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 753-761.	2.3	15
60	Sequential biochemotherapy for metastatic colorectal cancer using fluorouracil, folinic acid, thymopentin and interleukin-2: Clinical and immunological effects. <i>Annals of Oncology</i> , 1995, 6, 1011-1017.	0.6	14
61	First-in-Human Clinical Trials – What We Can Learn from Tragic Failures. <i>New England Journal of Medicine</i> , 2016, 375, 1788-1789.	13.9	14
62	Need for Redesigning Pharmacologic Research in Older Individuals. A Position Statement of the Geriatric Working Group of the Agenzia Italiana del Farmaco (AIFA). <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2011, 66A, 66-67.	1.7	12
63	Added therapeutic benefit and drug licensing. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 651-652.	21.5	12
64	Differential Expression of a New Tumor-Associated Antigen, TLP, During Human Colorectal Cancer Tumorigenesis. <i>American Journal of Pathology</i> , 1999, 154, 993-999.	1.9	11
65	Steps forward in regulatory pathways for acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 3-8.	2.9	11
66	<i>Implantation of microfabricated immunoisolating biocapsules</i> . , 1998, 3258, 40.		10
67	Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e83.	0.2	10
68	Evaluation of antigen specific recognition and cell mediated cytotoxicity by a modified lysis spot assay in a rat colon carcinoma model. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 9.	3.5	9
69	What we should learn from the London Olympics. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2013, 13, 1-3.	1.1	9
70	Atopic and Vernal Keratoconjunctivitis: A Model for Studying Atopic Disease. , 1999, 28, 88-94.		8
71	A new human tumor-associated antigen (TLP) is naturally expressed in rat DHD-K12 colorectal tumor cells. , 2000, 85, 540-544.		8
72	High CD169 Monocyte/Lymphocyte Ratio Reflects Immunophenotype Disruption and Oxygen Need in COVID-19 Patients. <i>Pathogens</i> , 2021, 10, 1639.	1.2	7

#	ARTICLE	IF	CITATIONS
73	Combination therapy with BRMs in cancer and infectious diseases. Mechanisms of Ageing and Development, 1997, 96, 103-116.	2.2	6
74	Vaccination with a synthetic nonapeptide expressed in human tumors prevents colorectal cancer liver metastases in syngeneic rats. International Journal of Cancer, 2004, 110, 70-75.	2.3	6
75	Innovative medicines: new regulatory procedures for the third millennium. Expert Opinion on Biological Therapy, 2015, 15, 5-8.	1.4	6
76	Expression profile of saccharide epitope CaMBr1 in normal and neoplastic tissue from dogs, cats, and rats: implication for the development of human-derived cancer vaccines. The Histochemical Journal, 1999, 31, 729-737.	0.6	4
77	Detection of high levels of <scp>S</scp>urvivinâ€“immunoglobulin <scp>M</scp> immune complex in sera from hepatitis <scp>C</scp> virus infected patients with cirrhosis. Hepatology Research, 2014, 44, 1008-1018.	1.8	4
78	Steps forward in regulatory pathways for acute and chronic heart failure. ESC Heart Failure, 2014, 1, 87-93.	1.4	4
79	Clinical trial publications: A sufficient basis for healthcare decisions?. European Journal of Internal Medicine, 2020, 71, 13-14.	1.0	4
80	Rationale for Therapeutic Approaches with Thymosin Î± 1, Interleukin 2 and Interferon in Combination with Chemotherapy. , 1992, , 275-281.		4
81	45 Atopy in twins. Journal of Allergy and Clinical Immunology, 1983, 71, 100.	1.5	3
82	The COVIDâ€“19 crisis as an opportunity to strengthen global regulatory coordination for sustained enhanced access to diagnostics and therapeutics. Clinical and Translational Science, 2021, 14, 777-780.	1.5	2
83	A critical evaluation of the process of drug discovery and evaluation: is the current approach the best possible one?. Annali Dell'Istituto Superiore Di Sanita, 2011, 47, 1.	0.2	2
84	Nerve Growth Factor Regulates the Production of Lung Mucins in a Transgenic Mice Model of Asthma. Journal of Allergy and Clinical Immunology, 2006, 117, S250.	1.5	1
85	survivin-IgM immuno complex: A novel candidate biomarker of cirrhosis to monitor patients progression towards hepatocellular carcinoma. Digestive and Liver Disease, 2009, 41, A13.	0.4	1
86	European regulatory experience with drugs for central nervous system disorders. Nature Reviews Drug Discovery, 2015, 14, 89-90.	21.5	1
87	Increasing the impact of Post Authorisation Safety Studies: transparency is key. European Journal of Internal Medicine, 2021, 83, 6-7.	1.0	1
88	524 POSTER Stimulatory effect of eucalyptus essential oil on macrophage/graulocyte phagocytic activity: in vitro and in vivo evidences. European Journal of Cancer, Supplement, 2006, 4, 159.	2.2	0
89	Lifestyle, Sports Activities and Allergic Diseases. Journal of Allergy and Clinical Immunology, 2006, 117, S294.	1.5	0
90	Epidemiological Study on Allergy and Asthma Phenotypes: Sub-clinical and Severe Asthma. Journal of Allergy and Clinical Immunology, 2006, 117, S1.	1.5	0

#	ARTICLE	IF	CITATIONS
91	A cinque anni dal Decreto sugli studi "non profit", come eravamo e dove siamo. Italian Journal of Medicine, 2010, 4, 5-7.	0.2	0
92	PCN99 ITALIAN MONITORING REGISTRY OF BEVACIZUMAB IN THE TREATMENT OF METASTATIC COLON RECTAL CARCINOMA. Value in Health, 2011, 14, A172.	0.1	0
93	Legends of allergy and immunology: Sergio Bonini. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3227-3229.	2.7	0